You searched for "macula"
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
How does cataract surgery affect eyes with wet AMD?
In this retrospective cohort study the authors’ primary objective was to assess whether cataract surgery in eyes with wet age-related macular degeneration (AMD), triggered its progression. The surgical group comprised of 40 eyes versus 42 eyes in the non-surgical control...
Insights in resistant diabetic macular oedema
5 August 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
Type 3 macular neovascularisation (MNV) due to age-related macular degeneration
3 October 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This paper systematically reviews and summarises the current knowledge on type 3 neovascularisation due to age-related macular degeneration which is defined as neovascularisation originating from the retinal deep capillary plexus that grows towards the outer retina often penetrating the level...
A case of ‘60-day glaucoma’
3 April 2023
| Jagruti Godhaniya, Rajan Paul
|
EYE - General
Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...
Bionic eyes: deciphering the neural circuitry of vision restoration
3 June 2024
| Muhammad Khursheed Ullah Khan Marwat
|
EYE - Cataract
As the boundaries between technology and biology blur, retinal prosthetics, often dubbed ‘bionic eyes’, present a ground-breaking paradigm shift in addressing blindness. This article delves into the captivating scientific intricacies of these neural interfaces, exploring their mechanisms of action, current...
Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference
Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...
Efficacy of intravitreal dexamethasone implant in patients with persistent macular oedema
1 December 2014
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Chronic cystoid macular oedema (CME) can develop secondary to various pathologies such as diabetic maculopathy, retinal vein occlusion and uveitis. It can cause significant visual impairment and macular damage. The therapeutic effect of corticosteroids in CME is through one or...
Time is vision in central retinal artery occlusion
Central retinal artery occlusion (CRAO) is a rare but devastating vascular episode that can have severe impact on vision. Treatment is very time-limited and needs to be initiated very quickly to salvage any vision. The majority of patients present to...
Longitudinal findings in children with neurofibromatosis type 1
3 September 2024
| Claire Howard
|
EYE - Neuro-ophthalmology
This retrospective chart review evaluates the ophthalmologic findings of children with neurofibromatosis type 1 (NF1). Optic pathway gliomas (OPGs) are the most common tumours found in children with NF1. Findings are compared between eyes with and without optic pathway gliomas...
The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD
1 April 2017
| Valentina Cipriani
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...
Eye Capacity: clinical need should drive ophthalmic service provision
1 February 2014
| Rod McNeil
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...
